Neurogene
NGNE
45 hedge funds and large institutions have $53.5M invested in Neurogene in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 17 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
16% more capital invested
Capital invested by funds: $46.1M → $53.5M (+$7.36M)
2% more funds holding
Funds holding: 44 → 45 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0.18% more ownership
Funds ownership: 3.69% → 3.88% (+0.18%)
48% less call options, than puts
Call options by funds: $268K | Put options by funds: $520K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.29M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$1.47M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.13M |
| 4 |
JP Morgan Chase
New York
|
+$828K |
| 5 |
D.E. Shaw & Co
New York
|
+$822K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.58M |
| 2 |
DAM
DLD Asset Management
New York
|
-$1.12M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.02M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$683K |
| 5 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$569K |
NGNE Hedge Fund Activity: Q3 2018 in Review
45 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2018, worth a combined $53.5M — up 16% from $46.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NGNE positions and 17 closed out — a net gain of 1 holder — while 16 added to existing stakes and 6 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $3.29M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.58M sold.
- 45 institutional investors held Neurogene (NGNE) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $53.5M of Neurogene stock for Q3 2018, up 16% quarter-over-quarter.
- 18 funds opened new Neurogene positions in Q3 2018 and 17 closed out, a net change of +1 holder.
- The largest Neurogene buyer in Q3 2018 was EcoR1 Capital, an estimated $3.29M added.
- The largest Neurogene seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2018.